• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, April 30 Aventis Pharma Ltd (APL), part of the Sanofi-Aventis Group, is set for more action in the local market, including acquisitions, partnerships and development of pharma compounds, said Dr Shailesh Ayyangar, APL’s Managing Director.

The company has just brought into India SoloStar, its pre-filled disposable insulin pen for use with its 24-hour insulin Lantus. The product’s entry into the local market comes within 16 months of its global launch. Priced at Rs 884, the device would be on par with Optiset, he said.

Optiset disposable pen and Autopen from Owen Mumford are the two other delivery devices that Sanofi-Aventis has for Lantus.

Since insulin is under price-control in the country, the price of SoloStar is approved by the Government, he said. About 34 per cent of the company’s products come under price control, he added. SoloStar is imported from Germany, though it attracts no customs duty.

More Stories on : Outlook | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bosch Chassis to make parts for Tata’s Nano

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line